|
1
|
Jemal A, Bray E, Center M, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sant M, Allemani C, Santaquilani M, Knijn
A, Marchesi F and Capocaccia R: EUROCARE Working Group. EUROCARE-4:
Survival of cancer patients diagnosed in 1995–1999. Results and
commentary. Eur J Cancer. 45:931–91. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Spiro SG and Silvestri GA: Oive hundred
years of lung cancer. Am J Respir Crit Care Med. 172:523–529. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Youlden DR, Cramb SM and Baade PD: The
International epidemiology of lung cancer: Geographical
distribution and secural trends. J Thorac Oncol. 3:818–831. 2008.
View Article : Google Scholar
|
|
5
|
Alberg AJ and Samet JM: Epidemiology of
lung cancer. Chest. 123 (1 Suppl):S21–S49. 2003. View Article : Google Scholar
|
|
6
|
Shepherd FA, Pereira Rodrigues J, Ciuleanu
T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S,
Smylie M, Martins R, et al: Erlotinib in previously treated
non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Neal JW: The SATURN trial: The value of
maintenance erlotinib in patients with non-small-cell lung cancer.
Future Oncol. 6:1827–1832. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ciuleanu T, Stelmakh L, Cicenas S,
Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK,
Klughammer B and Gonzalez EE: Efficacy and safety of erlotinib
versus chemotherapy in second-line treatment of patients with
advanced, non-small-cell lung cancer with poor prognosis (TITAN): A
randomized multicentre, open-label, phase 3 study. Lancet Oncol.
13:300–308. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (EURTAC): A
multicentre, open-label, randomized phase 3 study. Lancet Oncol.
13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Johnson BE and Jänne PA: Epidermal growth
factor receptor mutations in patients with non-small cell lung
cancer. Cancer Res. 65:7525–7529. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jackman DM, Yeap BY, Sequist LV, Lindeman
N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS,
et al: Exon 19 deletion mutations of epidermal growth factor
receptor are associated with prolonged survival in non-small cell
lung cancer patients treated with gefitinib or erlotinib. Clin
Cancer Res. 12:3908–3914. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Popat S, Hughes S, Papadopoulos P, Wilkins
A, Moore S, Priest K, Meehan L, Norton A and O'Brien M: Recurrent
responses to non-small cell lung cancer brain metastases with
erlotinib. Lung Cancer. 56:135–137. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grace Li: TLCR is endorsed by the Spanish
Lung Cancer Group (SLCG): New horizons for strong academic
collaboration in lung cancer. J Thorac Dis. Dec 5;E217–E218.
2013.PubMed/NCBI
|
|
15
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (EURTAC): A
multicentre, open-label, randomized phase 3 study. Lancet Oncol.
13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
